Mounjaro’s Label Expands; Type 1 Diabetes on the Rise; Testosterone and Afib

The FDA expanded the indication for tirzepatide (Mounjaro) to include reducing the risk of major adverse cardiovascular events in high-risk adults with type 2 diabetes, Eli Lilly announced.

Global type 1 diabetes prevalence is projected to rise 29% by 2049, jumping from 9.4 million cases in 2025 to 12.1 million, according to data from the upcoming European Association for the Study of Diabetes meeting.

In high metabolic risk pregnancies, metformin was linked to increased gestational age at delivery but failed to reduce gestational diabetes, a patient-level meta-analysis found. (NEJM Evidence)

Investigational multi-agonists amycretin and retatrutide appeared to yield even greater levels of weight loss than approved anti-obesity medications, according to a systematic review of randomized trials. (Annals of Internal Medicine)

People are turning to an unregulated gray market to source retatrutide ahead of its official approval. (The Guardian)

CVS and Walgreens have each filled roughly 100,000 prescriptions for $50-a-month obesity medications under Medicare’s Bridge program. (NPR)

Cardiovascular-kidney-metabolic syndrome was associated with higher risks of major blinding eye diseases, including cataracts, glaucoma, and age-related macular degeneration, U.K. Biobank data showed. (Eye)

New Mexico state funds will continue to cover gender-affirming care for minors despite federal cuts to Medicaid and CHIP coverage. (The Guardian)

An updated review returned mixed evidence about the relationship between testosterone and atrial fibrillation. (Journal of the Endocrine Society)

In adults with type 2 diabetes recovering from dialysis-requiring acute kidney injury, starting an SGLT2 inhibitor within 30 days of hospital discharge was linked with fewer adverse kidney events. (JAMA Network Open)

Roughly 14% of large employers said they already dropped or plan to drop coverage of GLP-1 drugs next year, according to a survey from the Business Group on Health. (Reuters via AOL)

Persistent use of tirzepatide (Zepbound) for weight loss in adults over 55 years was associated with lower long-term healthcare costs in a U.S. cohort study, driven in part by fewer inpatient and emergency department visits. (Diabetes, Obesity and Metabolism)